MedKoo Cat#: 145009 | Name: Brivaracetam, (αR,4R)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Brivaracetam, (αR,4R)- is a third-generation antiepileptic drug and anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Brivaracetam, (αR,4R)- has a high-affinity ligand for synaptic vesicle protein 2A. Brivaracetam, (αR,4R)- acts by binding to a synaptic vesicle glycoprotein, SV2A, and reducing the release of neurotransmitters. Brivaracetam, (αR,4R)- is primarily metabolized by hydrolysis, via amidase enzymes, to an inactive metabolite.

Chemical Structure

Brivaracetam, (αR,4R)-
Brivaracetam, (αR,4R)-
CAS#357337-00-9

Theoretical Analysis

MedKoo Cat#: 145009

Name: Brivaracetam, (αR,4R)-

CAS#: 357337-00-9

Chemical Formula: C11H20N2O2

Exact Mass: 212.1525

Molecular Weight: 212.29

Elemental Analysis: C, 62.24; H, 9.50; N, 13.20; O, 15.07

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Brivaracetam, (αR,4R)- ;(αR,4R)-Brivaracetam;
IUPAC/Chemical Name
(R)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
InChi Key
MSYKRHVOOPPJKU-RKDXNWHRSA-N
InChi Code
1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9-/m1/s1
SMILES Code
CCC[C@H]1CN([C@H](CC)C(N)=O)C(=O)C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 212.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Brivaracetam. 2021 Jun 21. PMID: 29999938. 2: Brivaracetam. Aust Prescr. 2017 Jun;40(3):112-113. doi: 10.18773/austprescr.2017.038. Epub 2017 May 10. PMID: 28798518; PMCID: PMC5478403. 3: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Brivaracetam. 2017 Oct 2. PMID: 31643850. 4: Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug- resistant epilepsy. Cochrane Database Syst Rev. 2022 Mar 14;3(3):CD011501. doi: 10.1002/14651858.CD011501.pub3. PMID: 35285519; PMCID: PMC8919456. 5: Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti- Masterson K, Rosenow F, Sirven JI, Smith B, Stern JM, Toledo M, Zipfel PA, Villanueva V. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. Epilepsy Behav. 2021 May;118:107939. doi: 10.1016/j.yebeh.2021.107939. Epub 2021 Apr 8. PMID: 33839453. 6: Dean L. Brivaracetam Therapy and CYP2C19 Genotype. 2018 May 15. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 29763212. 7: Khilari M, Nair PP, Jha BK. Brivaracetam: How Well Does It Fare as an Anti- Epileptic? A Review. Neurol India. 2021 Mar-Apr;69(2):284-293. doi: 10.4103/0028-3886.314584. PMID: 33904436. 8: Kappes JA, Hayes WJ, Strain JD, Farver DK. Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures. J Clin Pharmacol. 2017 Jul;57(7):811-817. doi: 10.1002/jcph.900. Epub 2017 Apr 10. PMID: 28394442. 9: Klein P, Tyrlikova I, Brazdil M, Rektor I. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother. 2016;17(2):283-95. doi: 10.1517/14656566.2016.1135129. Epub 2016 Jan 13. PMID: 26760311. 10: Brivaracetam (Brivlera) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Feb. PMID: 28846216. 11: Makke Y, Abou-Khalil B. Brivaracetam efficacy and safety in focal epilepsy. Expert Rev Neurother. 2019 Oct;19(10):955-964. doi: 10.1080/14737175.2019.1631160. Epub 2019 Jun 24. PMID: 31195850. 12: von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics. 2007 Jan;4(1):84-7. doi: 10.1016/j.nurt.2006.11.004. PMID: 17199019; PMCID: PMC7479692. 13: Karlov VA, Vlasov PN, Zhidkova IA, Kissin MY, Lebedeva AV, Lipatova LV, Mkrtchyan VR, Mukhin KY, Rudakova IG. Brivaratsetam v lechenii bol'nykh épilepsieĭ [Brivaracetam in the treatment of patients with epilepsy]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(9. Vyp. 2):55-62. Russian. doi: 10.17116/jnevro20171179255-62. PMID: 29213040. 14: Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. PMID: 26899665. 15: Lince-Rivera I, Córdoba NM, la Rosa JSO. Narrative review of brivaracetam for genetic generalized epilepsies. Seizure. 2022 Dec;103:72-81. doi: 10.1016/j.seizure.2022.10.009. Epub 2022 Oct 21. PMID: 36332461. 16: Hellerslia V, Asistido JM, Iyamu A. Brivaracetam for epilepsy. JAAPA. 2019 May;32(5):21-22. doi: 10.1097/01.JAA.0000554748.77547.f8. PMID: 31033711. 17: Verrotti A, Grasso EA, Cacciatore M, Matricardi S, Striano P. Potential role of brivaracetam in pediatric epilepsy. Acta Neurol Scand. 2021 Jan;143(1):19-26. doi: 10.1111/ane.13347. Epub 2020 Oct 13. PMID: 32966640. 18: Milovanović JR, Janković SM, Pejčić A, Milosavljević M, Opančina V, Radonjić V, Protrka Z, Kostić M. Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin Pharmacother. 2017 Sep;18(13):1381-1389. doi: 10.1080/14656566.2017.1359260. Epub 2017 Jul 28. PMID: 28737479. 19: Stephen LJ, Brodie MJ. Brivaracetam: a novel antiepileptic drug for focal- onset seizures. Ther Adv Neurol Disord. 2017 Nov 23;11:1756285617742081. doi: 10.1177/1756285617742081. PMID: 29399049; PMCID: PMC5784556. 20: Papaliagkas V, Notas K, Chatzikyriakou E, Moschou M, Bostanjopoulou S, Hadjigeorgiou G, Kimiskidis VK. Brivaracetam for dyskinetic cerebral palsy. Epileptic Disord. 2022 Jun 1;24(3):614-616. English. doi: 10.1684/epd.2022.1431. PMID: 35653104.